ALK and anaplastic large cell lymphoma: Subsequently, the efficacy of crizotinib against ALK+ ALCL was reported in several clinical trials [8,9], leading to its approval as a therapy for young adult or pediatric patients with relapsed or refractory ALCL in 2021.